MDXH -
MDxHealth SA Ordinary Shares
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 3.28 0.03 (0.76%) |
--- |
0.02 (0.46%) |
0.03 (0.76%) |
--- |
0.03 (0.76%) |
--- |
--- |
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Earnings & Ratios
- Basic EPS:
- Diluted EPS:
- Basic P/E:
- Diluted P/E:
- RSI(14) 1m:
- 100.0
- VWAP:
- 3.31
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences
Jan 12, 2026 13:00
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer
Jan 06, 2026 13:00
Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne
Sep 15, 2025 21:29
Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change
Jul 03, 2025 17:00
Global Molecular Diagnostics Market to Expand at a CAGR of ~9% by 2032 Due to the Rising Demand for Precision Medicine | DelveInsight
May 01, 2025 17:00
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide
Apr 08, 2025 08:48
Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results
Feb 26, 2025 21:00
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance
Jan 13, 2025 10:00
Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy Insights
Sep 13, 2024 00:30
Laboratory-Developed Tests (LDTs) World Market Forecast Report to 2028, with Coverage of the Effects of the FDA's New "Medical Devices: Laboratory Developed Tests" Rule, Passed in April 2024
Aug 15, 2024 14:58